155 related articles for article (PubMed ID: 32028640)
1. Polyurea Dendrimer Folate-Targeted Nanodelivery of l-Buthionine sulfoximine as a Tool to Tackle Ovarian Cancer Chemoresistance.
Cruz A; Mota P; Ramos C; Pires RF; Mendes C; Silva JP; Nunes SC; Bonifácio VDB; Serpa J
Antioxidants (Basel); 2020 Feb; 9(2):. PubMed ID: 32028640
[No Abstract] [Full Text] [Related]
2. l-Buthionine Sulfoximine Detection and Quantification in Polyurea Dendrimer Nanoformulations.
Mota P; Pires RF; Serpa J; Bonifácio VDB
Molecules; 2019 Aug; 24(17):. PubMed ID: 31461931
[TBL] [Abstract][Full Text] [Related]
3. Targeting Glutathione and Cystathionine β-Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.
Santos I; Ramos C; Mendes C; Sequeira CO; Tomé CS; Fernandes DGH; Mota P; Pires RF; Urso D; Hipólito A; Antunes AMM; Vicente JB; Pereira SA; Bonifácio VDB; Nunes SC; Serpa J
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31635026
[TBL] [Abstract][Full Text] [Related]
4. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
[TBL] [Abstract][Full Text] [Related]
5. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
6. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
7. Minimal ovarian upregulation of glutamate cysteine ligase expression in response to suppression of glutathione by buthionine sulfoximine.
Hoang YD; Avakian AP; Luderer U
Reprod Toxicol; 2006 Feb; 21(2):186-96. PubMed ID: 16183247
[TBL] [Abstract][Full Text] [Related]
8. Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione.
Mayer RD; Maines MD
Biochem Pharmacol; 1990 May; 39(10):1565-71. PubMed ID: 2337413
[TBL] [Abstract][Full Text] [Related]
9. Effects of cyclophosphamide and buthionine sulfoximine on ovarian glutathione and apoptosis.
Lopez SG; Luderer U
Free Radic Biol Med; 2004 Jun; 36(11):1366-77. PubMed ID: 15135172
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
11. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
12. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
14. Buthionine sulfoximine diverts the melanogenesis pathway toward the production of more soluble and degradable pigments.
Galván I; Wakamatsu K; Alonso-Alvarez C; Solano F
Bioorg Med Chem Lett; 2014 May; 24(9):2150-4. PubMed ID: 24703231
[TBL] [Abstract][Full Text] [Related]
15. Buthionine sulfoximine is a multitarget inhibitor of trypanothione synthesis in Trypanosoma cruzi.
Vázquez C; Mejia-Tlachi M; González-Chávez Z; Silva A; Rodríguez-Zavala JS; Moreno-Sánchez R; Saavedra E
FEBS Lett; 2017 Dec; 591(23):3881-3894. PubMed ID: 29127710
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
17. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
[TBL] [Abstract][Full Text] [Related]
18. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
19. Analytical and preparative separation of the diastereomers of L-buthionine (SR)-sulfoximine, a potent inhibitor of glutathione biosynthesis.
Campbell EB; Hayward ML; Griffith OW
Anal Biochem; 1991 May; 194(2):268-77. PubMed ID: 1677799
[TBL] [Abstract][Full Text] [Related]
20. Intracerebroventricular administration of L-buthionine sulfoximine: a method for depleting brain glutathione.
Pileblad E; Magnusson T
J Neurochem; 1989 Dec; 53(6):1878-82. PubMed ID: 2809598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
